Alector discontinues dementia drug and cuts staff by 49%
Alector has revealed that in a Phase III clinical trial in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) its candidate latozinemab (AL001) did not meet the clinical co-primary endpoint. Based on the results, the company has announced that the open-label extension portion of… Read More